A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 482
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : EC
Long Form : endometrial carcinoma
No. Year Title Co-occurring Abbreviation
1979 Evaluation of the carcinogenic effects of estrogens, progestins and oral contraceptives on cervix, uterus and ovary of animals and man. OC
1985 Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. AH
1986 The immune system during the pre-cancer and the early cancer period. IL-2 production by PBL from post-menopausal women with and without endometrial carcinoma. PBL
1987 Endometrial carcinoma: two diseases? AH, PR
1989 Endometrioid and clear cell carcinoma of the ovary. Factors affecting survival. CC
1989 [Diagnosis and treatment of endometrial hyperplasia]. EH, EPP, MPA
1990 Frequency and activity of autorosette forming cells in Con-A activated PBL from women with hyperplasia or carcinoma of the endometrium--possible role of estrogens. ---
1990 Is chromosome 10 a primary chromosomal abnormality in endometrial adenocarcinoma? ---
1990 [Doppler ultrasonic assessment with hemodynamics of gynecologic tumor]. BO, CC, KT, NU, OC, RI, TD
10  1990 [The association of uterine lipoma and cancer of the endometrium. Diagnostic and etiopathogenic approach]. CT, UL, US
11  1990 [When cancer of the endometrium is not a good cancer]. AH, PR
12  1991 Endometrial carcinoma: a pathologic evaluation of 142 cases with and without associated endometrial hyperplasia. EH
13  1992 Two types of endometrial papillary neoplasm. A morphometric study. AH, PA, PF
14  1993 Epidermal growth factor in human breast cancer, endometrial carcinoma and lung cancer. Its relationship to epidermal growth factor receptor, estradiol receptor and tumor TNM. BC, BM, EGF, LC, NB
15  1993 Is there an altered steroid profile in patients with endometrial carcinoma? ---
16  1994 Denser trabecular bone in women with endometrial carcinoma. BMD, HRT
17  1994 Prognostic factors and treatment outcome for patients with locally recurrent endometrial cancer. DSS, PC
18  1995 Endometrial carcinoma in elderly women. IC-IV
19  1995 Human endometrial carcinoma cells release factors which inhibit the growth of normal epithelial cells in culture. CM, NHEC, wtp53
20  1995 Surgical vs. clinical staging of endometrial carcinoma. The impact on treatment modification, morbidity and survival. ---
21  1995 Total suppression of spontaneous endometrial carcinoma in BDII/Han rats by melengestrol acetate. MGA
22  1995 Transforming growth factor-beta 1 mediates communication between human endometrial carcinoma cells and stromal cells. CMe, CMn, NSC, TGF-beta1
23  1995 [The prognostic factors in endometrial carcinoma (EC)]. ---
24  1996 Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use. BC, FIGO, RPCI
25  1996 Presenting symptoms of patients with endometrial carcinoma. Effect on prognosis. ---
26  1997 bcl-2 and p53 in endometrial adenocarcinoma. ERs, PRs
27  1997 Prognostic value of p53 and K-ras-2 topographic genotyping in endometrial carcinoma: a clinicopathologic and molecular comparison. ---
28  1998 Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. AI, BPE, CEH, CPF, MI, SEH
29  1998 Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma. ESC, IRS
30  1998 Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. MI
31  1999 Adjunctive use of the uterine artery resistance index in the preoperative prediction of myometrial invasion in endometrial carcinoma. TVUS
32  1999 Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma. ---
33  1999 Discordant expression of insulin-like growth factors and their receptor messenger ribonucleic acids in endometrial carcinomas relative to normal endometrium. IGF-IR, RT-PCR
34  1999 Endometrial cancer after tamoxifen treatment of breast cancer. Results of a retrospective cohort study. pts, RR, TAM
35  1999 hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. AEH, EH, MSI
36  1999 Prognostic significance of a novel proliferation marker, anti-repp 86, for endometrial carcinoma: a multivariate study. LI, mAb
37  2000 A case-control study of uterine endometrial cancer of pre- and post-menopausal women. ER, PCOS, PR
38  2000 Cyclin D1 expression in high-grade endometrial carcinomas--association with histologic subtype. ---
39  2000 Effect of tamoxifen treatment on the endometrial expression of human insulin-like growth factors and their receptor mRNAs. TAM
40  2000 Microsatellite analysis at 10q25-q26 in Sardinian patients with sporadic endometrial carcinoma: identification of specification patterns of genetic alteration. LOH, MSI, PCR
41  2000 Prognostic factors in young women with endometrial carcinoma: a report of 20 cases and review of literature. ---
42  2000 PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. EEC, MI, NEEC, SSCP
43  2000 [Are you prescribing fatal hormones? Bremen professor accuses physicians with unsubstantiated claims]. MC
44  2000 [Methylation and expression of the p16 gene in endometrial carcinoma]. AH, NE, SCH
45  2000 [Prognostic value of serum MMP-2 level in uterine cancer affected women]. MMP-2
46  2001 Fhit protein expression in endometrial cancers: no correlation with histological grade. ---
47  2001 Lactoferrin: a tamoxifen-responsive protein in normal and malignant human endometrial cells in culture. LF, NHEC, TAM
48  2001 MR imaging findings of uterine endometrial stromal sarcoma: differentiation from endometrial carcinoma. ESS
49  2001 Ultrasonographic detection of asymptomatic endometrial cancer in postmenopausal patients offers no prognostic advantage over symptomatic disease discovered by uterine bleeding. FIGO, TVS
50  2001 [Bax gene expression in endometrial carcinoma]. AH, NPE, SCH
51  2001 [Significance on expressions of Annexin-I and its correlative gene proteins in endometrial hyperplasia, atypical hyperplasia and endometrial carcinoma]. AtH, EH
52  2002 Amsterdam criteria II and endometrial cancer index cases for an accurate selection of HNPCC families. HNPCC
53  2002 Association of CD44 isoform immunohistochemical expression with myometrial and vascular invasion in endometrioid endometrial carcinoma. MI, VSI
54  2002 Association of endometrial thickness assessed at trans-vaginal ultrasonography to endometrial cancer in postmenopausal women asymptomatic or with abnormal uterine bleeding. AUB, TVUS
55  2002 Clinical usefulness of color Doppler ultrasound in patients with endometrial hyperplasia and carcinoma. EH, PI, PSV, RI, TV-CDU
56  2002 CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. MI, MMP-7
57  2002 Distinct PTEN mutational spectra in hereditary non-polyposis colon cancer syndrome-related endometrial carcinomas compared to sporadic microsatellite unstable tumors. BRR, CS, HNPCC, MMR, MSI
58  2002 Microsatellite instability and mutation analysis of candidate genes in unselected sardinian patients with endometrial carcinoma. IHC, MMR, MSI
59  2002 Microsatellite instability, loss of heterozygosity, and loss of hMLH1 and hMSH2 protein expression in endometrial carcinoma. FIGO, LOH, LVI, MMR, MSI
60  2002 MRI findings including gadolinium-enhanced dynamic studies of malignant, mixed mesodermal tumors of the uterus: differentiation from endometrial carcinomas. MMMT
61  2002 Outcome after salvage radiotherapy (brachytherapy +/- external) in patients with a vaginal recurrence from endometrial carcinomas. BT, IGR, RT, VR
62  2002 Papillary serous carcinoma of the peritoneum coexisting with or after endometrial carcinoma. EOC, ER, PR, PSCP
63  2002 Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. HNPCC
64  2002 [Recommendations for the oncologic pathology report and morphologic factors associated with prognosis in endometrial carcinoma]. ---
65  2003 CD44 variant 6 in endometrioid carcinoma of the uterus: its expression in the adenocarcinoma component is an independent prognostic marker. AEH
66  2003 Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. EECs
67  2003 Endoglin (CD105) expression in endometrial carcinoma. CHA, MV, SH, VEGF
68  2003 High-resolution methylation analysis of the hMLH1 promoter in sporadic endometrial and colorectal carcinomas. CRC, IHC, MMR, MSI, MSP, PCR
69  2003 Microvessel density (MVD) as a prognosticator in endometrial carcinoma. LVSI, MVD
70  2003 p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. OCCA
71  2003 p53 overexpression as a prognostic indicator in endometrial carcinoma. ---
72  2003 Progestin suppresses matrix metalloproteinase production in endometrial cancer. MPA
73  2004 Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma. ---
74  2004 Cell kinetics analysis in stage I endometrial carcinoma as determined by image cytometry and immunohistochemistry. Correlation with clinicopathologic characteristics. AgNOR, PI
75  2004 Clinicoprognostic significance of pRb1 pathway alterations in uterine endometrial adenocarcinoma. ---
76  2004 Role of lymphadenectomy in management of adenocarcinoma of the endometrium. LND
77  2004 The value of epithelial membrane antigen overexpression in hyperplastic and malignant endometrium and its relationship with steroid hormone receptor expression. ACH, BE, EMA OE, ER, PR, FIGO
78  2004 [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance]. BPE, EH
79  2004 [Significance of methylation and abnormal expression of p16 gene in endometrial carcinoma]. IHC, MSP
80  2005 Abnormal expression of period 1 (PER1) in endometrial carcinoma. CpG, Per1, RT-PCR
81  2005 Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas. LOH
82  2005 Endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia. AEH, BSO
83  2005 Expression of inhibitory natural killer receptors on tumor-infiltrating CD8+ T lymphocyte lineage in human endometrial carcinoma. NKRs, PBMCs, TILs
84  2005 High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. ELISA, IL-6, NEC, USPC
85  2005 Management of endometrial carcinoma with cervical involvement. An unsettled issue. ---
86  2005 Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? HNPCC, IHC, MMR
87  2005 PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma. ---
88  2005 [Significance of proliferating cell nuclear antigen (PCNA) index and microvessel density (MVD) in endometrial carcinoma]. MVD, PCNA
89  2006 Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. AEH
90  2006 Endometrial carcinoma with pleural metastasis: A case report. ---
91  2006 Expression of the cell cycle regulators p53, p21(WAF1/CIP1) and p16(INK4a) in human endometrial adenocarcinoma. LI
92  2006 Inhibin/activin subunits beta-A (-betaA) and beta-B (-betaB) are differentially localised in normal, hyperplastic and malignant human endometrial tissue. INHs
93  2006 Lack of correlation between leptin receptor expression and PI3-K/Akt signaling pathway proteins immunostaining in endometrioid-type endometrial carcinomas. H-score
94  2006 Lactoferrin immunoexpression in endometrial carcinomas: relationships with sex steroid hormone receptors (ER and PR), proliferation indices (Ki-67 and AgNOR) and survival. ER, ID, LF, PR
95  2006 Morules and morule-like features associated with carcinomas in various organs: report with immunohistochemical and molecular studies. NSEgamma, PB, WDFA
96  2006 PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations. ---
97  2006 RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma. ---
98  2006 The role of relaxin in endometrial cancer. RLN
99  2007 Application of laser capture microdissection and differential display technique for screening of pathogenic genes involved in endometrial carcinoma. BLAST, CDK7, FDD-PCR, LCM
100  2007 COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma. COX-2
101  2007 Expression of vascular endothelial growth factor and assessment of microvascular density with CD 34 and endoglin in proliferative endometrium, endometrial hyperplasia, and endometrial carcinoma. EH, MVD, PE, VEGF
102  2007 Impact of external beam adjuvant radiotherapy on health-related quality of life for long-term survivors of endometrial adenocarcinoma: a population-based study. EBRT, HRQoL
103  2007 Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. AH, CR, MPA
104  2007 P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome. ---
105  2007 Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. CRC, MMR, PI3K, PI3K
106  2007 Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. HNPCC, TVUS
107  2007 Syndecan-1, a key regulator of cell viability in endometrial cancer. ---
108  2007 Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients. DFS, EBRT, VB
109  2008 Diagnostic utility of phosphatase and tensin homolog, beta-catenin, and p53 for endometrial carcinoma by thin-layer endometrial preparations. PTEN
110  2008 Epigenetic signatures of familial cancer are characteristic of tumor type and family category. CRC, TSG
111  2008 Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction. AIs, ERE, GFP
112  2008 Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma. IGFBP-3
113  2008 Novel molecular profiles of endometrial cancer-new light through old windows. ---
114  2008 Outcome of uterine clear cell carcinomas compared to endometrioid carcinomas and poorly-differentiated endometrioid carcinomas. CC, HR
115  2008 P16 alterations increase the metastatic potential of endometrial carcinoma. ---
116  2008 Risk analysis of colorectal cancer in women with endometrial carcinoma. CRC, HNPCC, SIR
117  2008 The development of papillary serous carcinoma of the peritoneum subsequent to endometrial carcinoma: a case report and review of the literature. CK, PSCP
118  2008 The prevalence of mtDNA4977 deletion in primary human endometrial carcinomas and matched control samples. ---
119  2008 Total tissue lactate dehydrogenase activity in endometrial carcinoma. DPP III, LDH
120  2008 [Clinicopathological characteristics in hereditary nonpolyposis colorectal carcinoma-associated endometrial carcinoma]. HNPCC
121  2008 [Expression and activation of insulin receptor substrate-1 in endometrial carcinoma]. AHE, IRS-1
122  2009 A review of the applications of tissue microarray technology in understanding the molecular features of endometrial carcinoma. TMA
123  2009 A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer. BSO
124  2009 Allelic loss at TP53 in metastatic human endometrial carcinomas. LOH
125  2009 Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management. CRC, LS
126  2009 CK2beta is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation. ---
127  2009 Do microsatellite instability profiles really differ between colorectal and endometrial tumors? CRC, MSI
128  2009 Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium. AH
129  2009 Frequency and characteristics of endometrial carcinoma and atypical hyperplasia detected on routine infertility investigations in young women: a report of six cases. AH
130  2009 Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia. HNPCC, MMR
131  2009 Molecular classification of spontaneous endometrial adenocarcinomas in BDII rats. CDH1
132  2009 Novel expression profiles and invasiveness-related biology function of DKK1 in endometrial carcinoma. ---
133  2009 Sequential chemotherapy and irradiation in advanced stage endometrial cancer: A Gynecologic Oncology Group phase I trial of doxorubicin-cisplatin followed by whole abdomen irradiation. OS, PFS, WAI
134  2009 Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis. OC, OS, PFS
135  2009 Sulfatase activity in normal and neoplastic endometrium. DHEA, DHEAS, GC-MS, MMMT, UPSC
136  2009 Vascular pseudoinvasion in laparoscopic hysterectomy specimens for endometrial carcinoma: a grossing artifact? LH, TAH, VSI
137  2009 [Expression and function of cyclooxygenase-2 in endometrial carcinoma]. COX-2
138  2010 A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. CBR, mTOR, PI3K, PTEN, SD
139  2010 AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma. MALDI-TOF MS
140  2010 APC promoter hypermethylation is an early event in endometrial tumorigenesis. APC, E-cadherin
141  2010 Artemin stimulates oncogenicity and invasiveness of human endometrial carcinoma cells. ARTN
142  2010 DcR1 expression in endometrial carcinomas. IHC, NE, PCR, TRAIL
143  2010 Expression of vascular endothelial growth factor (VEGF) and assessment of microvascular density with CD34 as prognostic markers for endometrial carcinoma. MVD, VEGF
144  2010 Hormone prevention strategies for breast, endometrial and ovarian cancers. AI, CA, EOC, OC, SERMs
145  2010 L1CAM expression in endometrial carcinomas is regulated by usage of two different promoter regions. EMT, L1CAM
146  2010 Overexpressed epidermal growth factor receptor (EGFR)-induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogen-activated protein kinase signaling pathway. EGFR, MAPK, PRB
147  2010 Peritumoral lymphatic vessel density as a prognostic parameter in endometrial carcinoma: an immunohistochemical study. H and E, LN, LV, MV
148  2010 Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. ---
149  2010 Postoperative radiotherapy in stage I/II endometrial cancer: retrospective analysis of 883 patients treated at the University of Florence. BT, DMs, LR, RT, WPRT
150  2010 STAT3alpha is oncogenic for endometrial carcinoma cells and mediates the oncogenic effects of autocrine human growth hormone. hGH, STAT
151  2010 The pattern of p14ARF expression in primary and metastatic human endometrial carcinomas: correlation with clinicopathological features and TP53 pathway alterations. ---
152  2010 The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas. ER, IHC, PR
153  2010 [Study of dual ("joker") function of glucose in cancer patients]. CC, IGT
154  2011 Abnormal cervical cytology in the diagnosis of uterine papillary serous carcinoma: earlier detection of a poor prognostic cancer subtype? G3EC
155  2011 Comparison of FIGO 1989 and 2009 recommendations on staging of endometrial carcinoma: pathologic analysis and cervical status in 123 consecutive cases. FIGO
156  2011 Conservative treatment of early endometrial cancer: preliminary results of a pilot study. HSC, LNG-IUD, MA
157  2011 Detection and importance of micrometastases in histologically negative lymph nodes in endometrial carcinoma. RFS
158  2011 Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. EBRT, HR, LRR, PORTEC
159  2011 Identification of estrogen response element in the aquaporin-2 gene that mediates estrogen-induced cell migration and invasion in human endometrial carcinoma. AQP, IK
160  2011 Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. EBRT, EORTC, HRQL, PORTEC-1, SF-36
161  2011 MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo. TP53INP1
162  2011 Nuclear factor-kappaB2/p100 promotes endometrial carcinoma cell survival under hypoxia in a HIF-1alpha independent manner. HIF-1alpha
163  2011 Placing mitochondrial DNA mutations within the progression model of type I endometrial carcinoma. mtDNA
164  2011 Surgical cytoreduction in stage IV endometrioid endometrial carcinoma. OS, PFS
165  2011 The role of mast cells and angiogenesis in benign and malignant neoplasms of the uterus. MCD, MCs
166  2011 Vaginal and pelvic recurrences in stage I and II endometrial carcinoma--survival and prognostic factors. ---
167  2012 Clinical/pathologic features and patient outcome in early onset endometrial carcinoma: a population based analysis and an institutional perspective from the Detroit metropolitan area, Michigan. HR, MDCSS
168  2012 Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. CAH, CI, pCR, QCGC
169  2012 Endometrial Cancer: Comparison of Patients with Synchronous Primary Carcinoma of the Endometrium and Ovary vs. Endometrial Carcinoma with Ovarian Metastases. OC
170  2012 ETV5 cooperates with LPP as a sensor of extracellular signals and promotes EMT in endometrial carcinomas. EMT
171  2012 Expression profiles of carcinosarcoma of the uterine corpus-are these similar to carcinoma or sarcoma? CGH, CS, EMT, GSEA, US
172  2012 Fertility-sparing treatment using medroxyprogesterone acetate for endometrial carcinoma. CR, MPA
173  2012 Insulin promotes proliferation, survival, and invasion in endometrial carcinoma by activating the MEK/ERK pathway. ---
174  2012 Isolation and characterization of proliferative, migratory and multidrug-resistant endometrial carcinoma-initiating cells from human type II endometrial carcinoma cell lines. CICs, EC-CCs
175  2012 Less gastrointestinal toxicity after adjuvant radiotherapy on a small pelvic field compared to a standard pelvic field in patients with endometrial carcinoma. EBRT, EF, SmPF, StPF
176  2012 Loss of HLA class I and mismatch repair protein expression in sporadic endometrioid endometrial carcinomas. HLA, MMR
177  2012 Molecular bases of endometrial cancer: new roles for new actors in the diagnosis and the therapy of the disease. ---
178  2012 Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma? DOD, DUC, EEC
179  2012 Patients with atypical hyperplasia of the endometrium should be treated in oncological centers. AEH, DGCD
180  2012 Prediction of coexistent carcinomas risks by subjective EIN diagnosis and comparison with WHO classification in endometrial hyperplasias. EH, EIN, NPV, PPV, WHO
181  2012 Progestin treatment of atypical hyperplasia and well-differentiated adenocarcinoma of the endometrium to preserve fertility. AH
182  2012 Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma. IDO
183  2012 Technical challenges and limitations of current mouse models of ovarian cancer. EOC, GEM, OSE
184  2012 Trends in the utilization of adjuvant vaginal cuff brachytherapy and/or external beam radiation treatment in stage I and II endometrial cancer: a surveillance, epidemiology, and end-results study. EBRT, FIGO, SEER, VB
185  2012 [Analysis of the status of DACH1 gene promoter methylation in endometrial carcinoma and its clinical significance]. MSP
186  2012 [Correlations of p-AKT with PTEN, P53, HER-2 expressions in endometrial carcinoma and their relationship with patient survival]. NEC, p-Akt, PTEN
187  2012 [Expression of MMR in endometrial adenocarcinoma in women under 50 years old]. BMI, CAHE, MMR, NE, SHE
188  2012 [Fertility sparing management of endometrial adenocarcinoma and atypical hyperplasia: a literature review]. AH
189  2012 [Preliminary investigation of the expression and functions of insulin receptor isoforms in endometrial carcinoma]. DM, FIGO, IR-A, RT
190  2013 A prospective study of fertility-sparing treatment with megestrol acetate following hysteroscopic curettage for well-differentiated endometrioid carcinoma and atypical hyperplasia in young women. AH, MA
191  2013 A TrkB-STAT3-miR-204-5p regulatory circuitry controls proliferation and invasion of endometrial carcinoma cells. miRNAs, qRT-PCR
192  2013 Coexistent gestational choriocarcinoma and mixed adenocarcinoma of the uterus. ---
193  2013 Conservative treatment of early endometrial cancer. ---
194  2013 Cytologic features of the endometrial adenocarcinoma: comparison of ThinPrep and BD SurePath preparations. ---
195  2013 Daily schedule for high-dose-rate brachytherapy in postoperative treatment of endometrial carcinoma. EBI, G1-G2, HDR-BT
196  2013 Diagnostic approach and therapeutic management in early-stage endometrial cancer. ---
197  2013 Endometrial carcinoma: molecular alterations involved in tumor development and progression. ---
198  2013 Epithelial-to-mesenchymal transition and stem cells in endometrial cancer. CSC, EMT, MMMT
199  2013 Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. FRA
200  2013 Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib. ER, PR, FTS, MPA
201  2013 Improved survival of baby boomer women with early-stage uterine cancer: A Surveillance, Epidemiology and End Results (SEER) Study. BB, LN, PB, SEER
202  2013 LAPTM4B gene polymorphism and endometrial carcinoma risk and prognosis. CI, DFS, LAPTM4B, OS
203  2013 Let7a inhibits the growth of endometrial carcinoma cells by targeting Aurora-B. ---
204  2013 MicroRNA-182 promotes tumor cell growth by targeting transcription elongation factor A-like 7 in endometrial carcinoma. NEEC, TCEAL7
205  2013 Nationwide analysis on surgical staging procedures and systemic treatment for patients with endometrial cancer in Germany. LAN
206  2013 Ovarian transitional cell carcinoma represents a poorly differentiated form of high-grade serous or endometrioid adenocarcinoma. BTs, HGSC, TCC
207  2013 Progesterone receptor isoforms A and B: new insights into the mechanism of progesterone resistance for the treatment of endometrial carcinoma. PRs
208  2013 Proteomic identification of PKM2 and HSPA5 as potential biomarkers for predicting high-risk endometrial carcinoma. ---
209  2013 Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer. LND, P/PA, RSS, TD
210  2013 RNA interference-mediated targeting of DKK1 gene expression in Ishikawa endometrial carcinoma cells causes increased tumor cell invasion and migration. RNAi
211  2013 Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3beta-dependent protein degradation. Mcl-1, shRNA
212  2013 The effect of coexisting uterine myomas on clinico-pathological variables of endometrial carcinoma. LVSI
213  2013 Three-dimensional nuclear telomere architecture changes during endometrial carcinoma development. AH, SH
214  2013 Upregulation of TrkB promotes epithelial-mesenchymal transition and anoikis resistance in endometrial carcinoma. BDNF, EMT, RNAi
215  2013 Value of additional level sections in the evaluation of lymph nodes for endometrial carcinoma staging. FIGO, SLN
216  2013 [Correlation between estrogen receptor status and clinicopathologic parameters in endometrial cancer: a comparative study by immunohistochemistry using different scoring systems]. ER
217  2014 A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry. CI, IHC
218  2014 A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. CCC, HGSC, IHC, RPPA, SAM
219  2014 Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer. ---
220  2014 Clinical value of dna content assessment in endometrial cancer. DI
221  2014 Clinical value of DNA content assessment in endometrial cancer. DI
222  2014 Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary. CCC, DFS, OS, PSC
223  2014 Diagnostic role of circulating YKL-40 in endometrial carcinoma patients: a meta-analysis of seven related studies. ---
224  2014 Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. MATEs, OCTs, PCOS
225  2014 Distribution of estrogen and progesterone receptors isoforms in endometrial cancer. ---
226  2014 DNA methylation as a biomarker for the detection of hidden carcinoma in endometrial atypical hyperplasia. AH
227  2014 Does HBV infection increase risk of endometrial carcinoma? ---
228  2014 Efficacy of contemporary chemotherapy in stage IIIC endometrial cancer: a histologic dichotomy. DFS, EPM, HR
229  2014 Elevated MiR-222-3p promotes proliferation and invasion of endometrial carcinoma via targeting ERalpha. ---
230  2014 Endometrial cancer in Asian and American Indian/Alaskan Native women: tumor characteristics, treatment and outcome compared to non-Hispanic white women. AI/AN, AS, CSS, NHW
231  2014 Endometrial carcinoma in high-risk populations: is it time to consider a screening policy? LBC
232  2014 ETV5 transcription program links BDNF and promotion of EMT at invasive front of endometrial carcinomas. BDNF, TrkB
233  2014 Factors predicting nodal metastasis in endometrial cancer. CSI, DMI, LN, LVI, PPC, TS
234  2014 High nuclear expression of HDGF correlates with disease progression and poor prognosis in human endometrial carcinoma. HDGF, IHC
235  2014 Identification of chimeric TSNAX-DISC1 resulting from intergenic splicing in endometrial carcinoma through high-throughput RNA sequencing. CTCF, TSNAX-DISC1
236  2014 Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device metformin weight loss in endometrial cancer (feMME) trial. LNG-IUD, pCR
237  2014 Isthmocervical labelling and SPECT/CT for optimized sentinel detection in endometrial cancer: technique, experience and results. LN, NPV, SLN, SPECT/CT
238  2014 Management of endometrial cancer in Italy: a national survey endorsed by the Italian Society of Gynecologic Oncology. SIOG
239  2014 miR-124 functions as a tumor suppressor in the endometrial carcinoma cell line HEC-1B partly by suppressing STAT3. miR-124, miRNAs, STAT3
240  2014 Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables. BMI, MMR
241  2014 Nationwide analysis on surgical procedures for patients with endometrial cancer in Germany: results of the AGO pattern of care studies from the years 2013, 2009, and 2006. LAN, LSA
242  2014 Prognostic value of cytoplasmic expression of S100A4 protein in endometrial carcinoma. PR, qRT-PCR
243  2014 Rictor is an independent prognostic factor for endometrial carcinoma. AUC, OS
244  2014 Role of local bioactivation of vitamin D by CYP27A1 and CYP2R1 in the control of cell growth in normal endometrium and endometrial carcinoma. NE, VD, VDR
245  2014 Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. DNMT1
246  2014 SERPINA3 promotes endometrial cancer cells growth by regulating G2/M cell cycle checkpoint and apoptosis. ER
247  2014 Significance of foamy histiocytes in cervical smears from postmenopausal women. AEC, BEC, FH, NS
248  2014 Survival of women with clear cell and papillary serous endometrial cancer after adjuvant radiotherapy. CHT, DMFS, EBRT, LNE, LRFS, OS, pts, RT
249  2014 The long non-coding RNA HOTAIR is upregulated in endometrial carcinoma and correlates with poor prognosis. FFPE, HOX, lncRNA, lncRNAs
250  2014 The prognostic role of preoperative serum CA 125 levels in patients with endometrial carcinoma. DFS, OS
251  2014 Type II endometrial cancer in Hispanic women: tumor characteristics, treatment and survival compared to non-Hispanic white women. CSS, HW, NHW, OS, SEER
252  2014 [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia]. CAH, CR
253  2014 [MicroRNA expression signature profile and its clinical significance in endometrioid carcinoma]. IHC, miRNA
254  2015 Aberrant promoter hypermethylation of p16 gene in endometrial carcinoma. ORs
255  2015 Adiponectin mediates antiproliferative and apoptotic responses in endometrial carcinoma by the AdipoRs/AMPK pathway. ELISA
256  2015 AMF/PGI-mediated tumorigenesis through MAPK-ERK signaling in endometrial carcinoma. AMF, PGI
257  2015 Analysis of an independent tumor suppressor locus telomeric to Tp53 suggested Inpp5k and Myo1c as novel tumor suppressor gene candidates in this region. PI
258  2015 Annexin A4 and cancer. Anxa4, BC, CRC, ESCC, GC, HCC, LC, MM, MSGT, OCCC, OSCC, PCa, PCC, RCC
259  2015 Application of Combined Two-Dimensional and Three-Dimensional Transvaginal Contrast Enhanced Ultrasound in the Diagnosis of Endometrial Carcinoma. CEUS
260  2015 Association of specific PTEN/10q haplotypes with endometrial cancer phenotypes in African-American and European American women. AA, CS, EA
261  2015 Cancer Incidence in Patients with Atypical Endometrial Hyperplasia Managed by Primary Hysterectomy or Fertility-sparing Treatment. AEH
262  2015 Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies. MSI, PDTX
263  2015 Clinical significance of Sam68 expression in endometrial carcinoma. ---
264  2015 Clinicopathological Significance and Potential Drug Target of CDKN2A/p16 in Endometrial Carcinoma. OR
265  2015 Concurrent endometrial carcinoma in hysterectomy specimens in patients with histopathological diagnosis of endometrial hyperplasia in curettage specimens. AEH, EH
266  2015 Correlation between transcription factor activator protein-2beta (TFAP-2beta) and endometrial carcinoma. BMI, HDL, LDL, RT-PCR, TFAP-2beta
267  2015 Curcumin suppresses migration and invasion of human endometrial carcinoma cells. ERK, MMP
268  2015 Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. ---
269  2015 Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia. AEH, Dusp6
270  2015 Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor. EGFR, HER2
271  2015 Endometrial Adenocarcinoma in A 31-Year Old Woman: A Case Report. ---
272  2015 Endometrial adenocarcinoma in young-aged women: a Turkish population study. BMI
273  2015 Endometrial carcinoma in Portugal: demographic, diagnostic and treatment changes in the last 5 decades. ---
274  2015 Endometrial Carcinomas With Clear Cells: A Study of a Heterogeneous Group of Tumors Including Interobserver Variability, Mutation Analysis, and Immunohistochemistry With HNF-1beta. CC, SC
275  2015 Enolase-1 is a therapeutic target in endometrial carcinoma. EMT, HEEC
276  2015 Expression of ER, PR, C-erbB-2 and Ki-67 in Endometrial Carcinoma and their Relationships with the Clinicopathological Features. ER, PR
277  2015 Failure to recognize preoperatively high-risk endometrial carcinoma is associated with a poor outcome. DSS, OS, RFS
278  2015 Frequent SOCS3 and 3OST2 promoter methylation and their epigenetic regulation in endometrial carcinoma. TSA, TSGs
279  2015 HGF and c-Met in pathogenesis of endometrial carcinoma. HGF
280  2015 Hsa-microRNA-181a is a regulator of a number of cancer genes and a biomarker for endometrial carcinoma in patients: a bioinformatic and clinical study and the therapeutic implication. DAVID, KEGG
281  2015 Identification of subgroup-specific miRNA patterns by epigenetic profiling of sporadic and Lynch syndrome-associated colorectal and endometrial carcinoma. CRC, miRNAs, MMR
282  2015 Imaging in endometrial carcinoma. CT, FIGO, MRI, PET, TVUS
283  2015 Immunohistochemical Comparison of Ovarian and Uterine Endometrioid Carcinoma, Endometrioid Carcinoma With Clear Cell Change, and Clear Cell Carcinoma. CCC, EC-CC
284  2015 Leptin Inhibits the Apoptosis of Endometrial Carcinoma Cells Through Activation of the Nuclear Factor kappaB-inducing Kinase/IkappaB Kinase Pathway. IKK, NIK
285  2015 Long Non-Coding RNAs in Endometrial Carcinoma. lncRNAs
286  2015 Metformin down-regulates endometrial carcinoma cell secretion of IGF-1 and expression of IGF-1R. IGF, IGF-1R
287  2015 MicroRNA-424 suppresses estradiol-induced cell proliferation via targeting GPER in endometrial cancer cells. GPER, miRNAs
288  2015 miR-34c plays a role of tumor suppressor in HEC‑1-B cells by targeting E2F3 protein. ---
289  2015 Mitochondrial changes in endometrial carcinoma: possible role in tumor diagnosis and prognosis (review). mtDNA
290  2015 Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. CCC, EOC, HGSC, IHC, LGSC, MC
291  2015 MRI for local staging of endometrial carcinoma: Is endovenous contrast medium administration still needed? DWI, T2WI
292  2015 Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing. EMT, EZH2, MET, mutp53, wtp53
293  2015 Napsin A is frequently expressed in clear cell carcinoma of the ovary and endometrium. CA, EM, HGSC, O-EC, OCCCs, Pax, TTF
294  2015 Overexpression of ANCCA/ATAD2 in endometrial carcinoma and its correlation with tumor progression and poor prognosis. ANCCA, CI, DFS, FIGO, HR, OS
295  2015 Para-aortic and Pelvic Radiotherapy, an Effective and Safe Treatment in Advanced-stage Uterine Cancer. EBRT, EF, VBT
296  2015 Shadow cell differentiation in endometrioid carcinomas of the uterus. Its frequent occurrence and beta-catenin expression. SCD
297  2015 Surgical and systemic management of endometrial cancer: an international survey. CE, LND, NE, SE
298  2015 Survival impact of cytoreduction to microscopic disease for advanced stage cancer of the uterine corpus: a retrospective cohort study. CS, OS, RD, UPSC/CC
299  2015 The antitumor effect of metformin with and without carboplatin on primary endometrioid endometrial carcinoma in vivo. ---
300  2015 The association between XRCC1 genetic polymorphisms and the risk of endometrial carcinoma in Chinese. CRS-PCR, PCR-RFLP, vs, XRCC1
301  2015 The effect of lymphadenectomy and radiotherapy on recurrence and survival in endometrial carcinoma. Experience in a population reference centre. BT, DFS, EBI, OS
302  2015 The significance of the altered expression of lysophosphatidic acid receptors, autotaxin and phospholipase A2 as the potential biomarkers in type1 endometrial cancer biology. ATX, BMI, FIGO, LPA, LPARs, PLA2
303  2015 Upregulation of mitogen-inducible gene 6 triggers antitumor effect and attenuates progesterone resistance in endometrial carcinoma cells. Mig-6, MMP
304  2015 Which is the appropriate surgical procedure for Stage I endometrial carcinoma? ---
305  2015 YT521 promotes metastases of endometrial cancer by differential splicing of vascular endothelial growth factor A. VEGF-A
306  2015 [Clinicopathologic features observation of ovarian transitional cell tumors]. HGSC, SC, TCC
307  2015 [Molecular pathology of endometrial carcinoma - areview]. ---
308  2016 ACR Appropriateness Criteria Management of Recurrent Endometrial Cancer. ---
309  2016 Age cut-off for reporting endometrial cells on a Papanicolaou test: 50 years may be more appropriate than 45 years. AGC-NOS, Pap
310  2016 An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial Carcinoma. ECOG, OS, PFS, RT
311  2016 Biological Effects of Temsirolimus on the mTOR Pathway in Endometrial Carcinoma: A Pharmacodynamic Phase II Study. ---
312  2016 Clinicopathologic characteristics and treatment features of women with the incidental diagnosis of endometrial adenocarcinoma during infertility follow-up in Ankara, Turkey. ART, IUD
313  2016 Distinct expression profile of lncRNA in endometrial carcinoma. NE
314  2016 EFEMP1 is repressed by estrogen and inhibits the epithelial-mesenchymal transition via Wnt/beta-catenin signaling in endometrial carcinoma. ChIP, EMT, ERE
315  2016 Elevated STMN1 promotes tumor growth and invasion in endometrial carcinoma. MMP
316  2016 Endometrial Cancer Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression Increases with Body Mass Index and Is Associated with Pathologic Extent and Prognosis. BMI, CI, DFS, IGF1R, OS, pT
317  2016 Endometrial cancer: Not your grandmother's cancer. ---
318  2016 Endometrial carcinoma-related genetic factors: application to research and clinical practice in China. ---
319  2016 Evaluating L1CAM expression in human endometrial cancer using qRT-PCR. IHC, L1CAMEXP, L1CAMMET
320  2016 External validation of non-imaging models for predicting distant metastasis in patients with endometrial cancer. AUCs
321  2016 Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia. AEH, ART, EMB, MPA
322  2016 Flow cytometer analysis of cell apoptosis of endometrial carcinoma with Wnt10b. FACS, MTT
323  2016 Fluorescence-assisted sentinel (SND) and pelvic node dissections by single-port transvaginal laparoscopic surgery, for the management of an endometrial carcinoma (EC) in an elderly obese patient. ICG
324  2016 Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway. HDAC
325  2016 Impact of oviductal versus ovarian epithelial cell of origin on ovarian endometrioid carcinoma phenotype in the mouse. GEMMs, OSE, TAM
326  2016 Kruppel-like factor 4 (KLF-4) inhibits the epithelial-to-mesenchymal transition and proliferation of human endometrial carcinoma cells. EMT, KLF4, KLFs
327  2016 LncRNA FER1L4 suppresses cancer cell proliferation and cycle by regulating PTEN expression in endometrial carcinoma. lncRNAs, PTEN
328  2016 LncRNA-MEG3 inhibits cell proliferation of endometrial carcinoma by repressing Notch signaling. shMEG3
329  2016 Loss of p27 Associated with Risk for Endometrial Carcinoma Arising in the Setting of Obesity. TSC2
330  2016 Micronucleus testing as a cancer detector: endometrial hyperplasia to carcinoma. EH
331  2016 MicroRNA-340 Inhibits Tumor Cell Proliferation and Induces Apoptosis in Endometrial Carcinoma Cell Line RL 95-2. Bcl-2, KIP, miR-340
332  2016 MicroRNA-372 inhibits endometrial carcinoma development by targeting the expression of the Ras homolog gene family member C (RhoC). Bax, CDK2, miR-372, MMP2, RhoC
333  2016 MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-alpha. TGFA
334  2016 Microsatellite polymorphism in the P1 promoter region of the IGF‑1 gene is associated with endometrial cancer. IGF, IGFBP
335  2016 MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. MIIP
336  2016 New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. ---
337  2016 Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer. CEH
338  2016 Oncologic Safety of Laparoscopy in the Surgical Treatment of Type II Endometrial Cancer. ---
339  2016 Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. CA, Cy, HGSOC, IHC, NGS, OE, WT
340  2016 Outcome and Follow-up of Patients with Endometrial Carcinoma Diagnosed on Operative Hysteroscopic Resection Specimens. FIGO
341  2016 Paired boxed gene 1 expression: A single potential biomarker for differentiating endometrial lesions associated with favorable outcomes in patients with endometrial carcinoma. PAX1
342  2016 Pathologic Findings in Prophylactic and Nonprophylactic Hysterectomy Specimens of Patients With Lynch Syndrome. EECs, LS, NPH, PH
343  2016 Predictive Capacity of 3 Comorbidity Indices in Estimating Survival Endpoints in Women With Early-Stage Endometrial Carcinoma. AACCI, ACE-27, CCI, RFS
344  2016 Prognostic significance of CD169-positive lymph node sinus macrophages in patients with endometrial carcinoma. CTL, LN, RLN
345  2016 Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth. PP2A
346  2016 Reflex test reminders in required cancer synoptic templates decrease order entry error: An analysis of mismatch repair immunohistochemical orders to screen for Lynch syndrome. IHC, LS, MMR, PostImp, PreImp, S/O
347  2016 Role of Liquid-based Cytology and Cell Block in the Diagnosis of Endometrial Lesions. CB, LBC
348  2016 S100A4 accelerates the proliferation and invasion of endometrioid carcinoma and is associated with the "MELF" pattern. ALDH, MELF
349  2016 Salvage Versus Adjuvant Radiation Treatment for Women With Early-Stage Endometrial Carcinoma: A Matched Analysis. ART, DSS, OS, SRT
350  2016 Stromal Clues in Endometrial Carcinoma: Loss of Expression of beta-Catenin, Epithelial-Mesenchymal Transition Regulators, and Estrogen-Progesterone Receptor. ER, PR
351  2016 Survival endpoints for young women with early stage uterine endometrioid carcinoma: a matched analysis. DSS, OS
352  2016 Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8). OC
353  2016 The clinical significance of K-ras mutation in endometrial "surface epithelial changes" and their associated endometrial adenocarcinoma. ECs, MGH, WD
354  2016 The R156R ERCC2 polymorphism as a risk factor of endometrial cancer. OR, PCR-RFLP
355  2016 The rs6983267 SNP and long non-coding RNA CARLo-5 are associated with endometrial carcinoma. NETs, PCR, SNP
356  2016 Upregulation of microRNA‑337 promotes the proliferation of endometrial carcinoma cells via targeting PTEN. miRs, PTEN
357  2016 Wilms' tumor 1 protein expression in endometrial adenocarcinoma and endometrial intra-epithelial neoplasia. EIN, WT1
358  2016 [Coexpression of MAP2K4 and vimentin proteins in human endometrial carcinoma and its clinicopathological significance]. ---
359  2016 [Expressions of DAPK3 and c-Myc in endometrial cancer and their relationship with the patients' prognosis]. ---
360  2016 [Security of hormone replacement therapy among postoperative patients with endometrial carcinoma: a Meta-analysis]. HRT
361  2016 [The Expression of Pokemon in Endometrial Carcinoma Tissue and the Correlation with Mutant p53]. ---
362  2017 Aberrant MicroRNA Expression in Patients With Endometrial Cancer. CA125, HE4, miRNA
363  2017 ABO Blood Group and Endometrial Carcinoma: A Preliminary Single-Center Experience from Saudi Arabia. BMI
364  2017 Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer. ---
365  2017 Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications. AOVT, ER, HR, PR
366  2017 Autocrine Prolactin Stimulates Endometrial Carcinoma Growth and Metastasis and Reduces Sensitivity to Chemotherapy. hPRL
367  2017 Biological markers with potential clinical value in endometrial cancer - review of the literature. ---
368  2017 DICER1 regulates endometrial carcinoma invasion via histone acetylation and methylation. EMT
369  2017 Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas. CC, CS, USC
370  2017 DNMT1 regulates human endometrial carcinoma cell proliferation. CCK-8, DNMT1, NF-kappaBIA
371  2017 DPPIV promotes endometrial carcinoma cell proliferation, invasion and tumorigenesis. DPP-IV, HIF1A, VEGF-A
372  2017 Effect of Momordica charantia protein on proliferation, apoptosis and the AKT signal transduction pathway in the human endometrial carcinoma Ishikawa H cell line in vitro. ---
373  2017 Endoplasmic reticulum stress-mediated membrane expression of CRT/ERp57 induces immunogenic apoptosis in drug-resistant endometrial cancer cells. DOX, ER
374  2017 Estrogen and insulin synergistically promote type 1 endometrial cancer progression. ORs
375  2017 Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. BMI, CI, DSS, ER, HR, IHC, L1CAM, LVSI, OS, POLE, PR, ProMisE, PTEN, WT
376  2017 Expression and clinical significance of ARTN and MMP-9 in endometrial carcinoma. ARTN, MMP-9
377  2017 Expression of EZH2 in endometrial carcinoma and its effects on proliferation and invasion of endometrial carcinoma cells. EZH2
378  2017 Expression Profiles of Endometrial Carcinoma by Integrative Analysis of TCGA Data. DEGs, DEMs, TFs
379  2017 Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma. ---
380  2017 Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women. CAH, CR, GnRHa
381  2017 Haemoglobin monitoring in endometrial cancer patients undergoing radiotherapy. EBRT, Hb, HDR-BT, OS, RT
382  2017 Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER+ endometrial carcinoma cells. BC, si, TAM, TFF3
383  2017 Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. BMI, MIS
384  2017 Increase in proteins involved in mitochondrial fission, mitophagy, proteolysis and antioxidant response in type I endometrial cancer as an adaptive response to respiratory complex I deficiency. ---
385  2017 Influence of Comorbidity on the Risk of Death: A Single Institution Study of 1132 Women With Early-stage Uterine Cancer. aaCCI, DSS, LVSI, OS, RFS
386  2017 Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup. EDM, MMR, p53wt, POLE, SC
387  2017 Is Older Age a Real Adverse Prognostic Factor in Women With Early-Stage Endometrial Carcinoma? A Matched Analysis. DSS, LVSI, OS
388  2017 L1CAM and HER2 Expression in Early Endometrioid Uterine Cancer. ---
389  2017 Long non-coding RNA LINC00672 contributes to p53 protein-mediated gene suppression and promotes endometrial cancer chemosensitivity. lincRNAs
390  2017 Long non-coding RNA TUG1 promotes endometrial cancer development via inhibiting miR-299 and miR-34a-5p. lncRNAs, TUG1
391  2017 MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma. IHC, miR-29b, MVD
392  2017 MicroRNA-424/E2F6 feedback loop modulates cell invasion, migration and EMT in endometrial carcinoma. miR-424
393  2017 MiR-106a promotes tumor growth, migration, and invasion by targeting BCL2L11 in human endometrial adenocarcinoma. ---
394  2017 miR-944 acts as a prognostic marker and promotes the tumor progression in endometrial cancer. CADM2, FIGO, miR-944
395  2017 Over-expression of miR-1271 inhibits endometrial cancer cells proliferation and induces cell apoptosis by targeting CDK1. CDK1, miRNAs
396  2017 Overexpression of erythropoietin-producing hepatocyte receptor B4 and ephrin-B2 is associated with estrogen receptor expression in endometrial adenocarcinoma. EphB4, ER, PR
397  2017 Pancreatic non-functioning neuroendocrine tumor: a new entity genetically related to Lynch syndrome. CRC, IHC, LS, MMR, MSI, PCR, PNETs
398  2017 Panobinostat Enhances Growth Suppressive Effects of Progestin on Endometrial Carcinoma by Increasing Progesterone Receptor and Mitogen-Inducible Gene-6. HDAC, MIG6, MPA, mRNA, PR
399  2017 Patterns of adjuvant radiation usage and survival outcomes for stage I endometrial carcinoma in a large hospital-based cohort. EBRT, NCDB, OS, RT
400  2017 Polymerase epsilon (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. IHC, POLE
401  2017 Postablation Endometrial Carcinoma. EA, GEA, PAEC, RHS
402  2017 Preoperative assessment in endometrial cancer. Is triage for lymphadenectomy possible? AUC, LND, QOL, ROC, TH-BSO
403  2017 Preoperative thrombocytosis as a prognostic factor in endometrioid-type endometrial carcinoma. DFS, FIGO, OS
404  2017 Preventive Efficacy of Vanillic Acid on Regulation of Redox Homeostasis, Matrix Metalloproteinases and Cyclin D1 in Rats Bearing Endometrial Carcinoma. CAT, GPx, LOOH, MNNG, SOD, TBARS
405  2017 Quantitative evaluation of diffusion-kurtosis imaging for grading endometrial carcinoma: a comparative study with diffusion-weighted imaging. ADC, AUC, Dapp, DKI, DWI, Kapp, MRI, ROC
406  2017 Reciprocal crosstalk between endometrial carcinoma and mesenchymal stem cells via transforming growth factor-beta/transforming growth factor receptor and C-X-C motif chemokine ligand 12/C-X-C chemokine receptor type 4 aggravates malignant phenotypes. CXCL12, eMSCs, TGF
407  2017 Regulation of NEAT1/miR-214-3p on the growth, migration and invasion of endometrial carcinoma cells. ---
408  2017 Role of HAND2 gene and protein expression in endometrial carcinoma. RT-PCR
409  2017 Silencing of CXCR4 and CXCR7 expression by RNA interference suppresses human endometrial carcinoma growth in vivo. ---
410  2017 Stromal p16 expression is significantly increased in endometrial carcinoma. AH/EIN, SC, SEIC
411  2017 Survival outcomes and patterns of failure in women with stage IIIC2 endometrial carcinoma. CRT, CT, DSS, MVA, OS
412  2017 The expression of ER, PR in endometrial cancer and analysis of their correlation with ERK signaling pathway. ER, ERK, PR
413  2017 The impact of lymphadenectomy on survival endpoints in women with early stage uterine endometrioid carcinoma: A matched analysis. DSS, LA, LUS, OS
414  2017 The role of metastasis-associated in colon cancer 1 (MACC1) in endometrial carcinoma tumorigenesis and progression. CDK2, E-ca, MACC1, miRNA, MMP2, N-Ca, siRNA
415  2017 The role of the SDF-1/ CXCR7 axis on the growth and invasion ability of endometrial cancer cells. CXCR4, SDF-1
416  2018 A Matched Analysis on the Prognostic Impact of Race on Survival Endpoints of Women with Early-Stage Endometrial Cancer. AA, DSS, LVSI, NAA, OS, RFS
417  2018 A network meta-analysis of comparison of operative time and complications of laparoscopy, laparotomy, and laparoscopic-assisted vaginal hysterectomy for endometrial carcinoma. LAVH, RCTs, SUCRA, WMD
418  2018 A Pathological Study Using 2014 WHO Criteria Reveals Poor Prognosis of Grade 3 Ovarian Endometrioid Carcinomas. HGSC, PFS
419  2018 Adjuvant External Radiation Impacts Outcome of Pelvis-limited Stage III Endometrial Carcinoma: A Multi-institutional Study. CRT, CT, MVA, OS, PL, RFS, RT
420  2018 Altered expression of lysophosphatidic acid receptors, in association with the synthesis of estrogens and androgens in type 1 endometrial cancer biology. CYP19A1, LPA, SRD5A2
421  2018 Are endometrial cancer radiotherapy results age related? CSS, PRT, VCR
422  2018 Association between RAD51 135 G/C polymorphism and risk of 3 common gynecological cancers: A meta-analysis. CI, OC, OR
423  2018 Bioinformatics analysis of key differentially expressed genes in well and poorly differentiated endometrial carcinoma. DEGs, mi
424  2018 Brain metastases in patients with low-grade endometrial carcinoma. OS
425  2018 Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis. CA, CCC, LNM, OS, PFS
426  2018 Contrast enhanced ultrasound in diagnosis of endometrial carcinoma and endometrial hyperplasia. CEUS, EH
427  2018 Contrast-enhanced ultrasound in the diagnosis of endometrial carcinoma: A meta-analysis. CEUS, CI, DOR, SROC
428  2018 Correlation of MACC1/c-Myc Expression in Endometrial Carcinoma with Clinical/Pathological Features or Prognosis. IHC
429  2018 Decreased expression of TFAP2B in endometrial cancer predicts poor prognosis: A study based on TCGA data. CI, GSEA, OS, TFAP-2beta
430  2018 Does Age-Adjusted Charlson Comorbidity Score Impact Survival Endpoints in Women with Federation of Gynecology and Obstetrics-Stage III Endometrial Cancer? aaCCI, DSS, OS
431  2018 Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study. CIs, GOG, HRs, NHB, NHW, SES
432  2018 Establishment of a nine-gene prognostic model for predicting overall survival of patients with endometrial carcinoma. OS
433  2018 Expression of Estrogen Receptors (ER), Progesterone Receptors (PR) and HER-2/neu receptors in Endometrial Carcinoma and their associations with histological types, grades and stages of the tumor. ER, PR
434  2018 Extended duration of dilator use beyond 1year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy. BT, VD, VS
435  2018 Fatostatin suppresses growth and enhances apoptosis by blocking SREBP-regulated metabolic pathways in endometrial carcinoma. SREBP
436  2018 Fertility Sparing Treatment in Patients With Early Stage Endometrial Cancer, Using a Combination of Surgery and GnRH Agonist: A Monocentric Retrospective Study and Review of the Literature. EIN, G1EC, GnRH
437  2018 Gene Promoter Methylation in Endometrial Carcinogenesis. AH
438  2018 Genetic polymorphisms in CDH1 are associated with endometrial carcinoma susceptibility among Chinese Han women. CDH1, htSNPs
439  2018 Hesperidin promotes programmed cell death by downregulation of nongenomic estrogen receptor signalling pathway in endometrial cancer cells. ESRI, Hsd, PS
440  2018 High preoperative Glasgow prognostic score is a negative prognostic factor for patients with endometrial carcinoma. GPS, OS, PFS
441  2018 Integrating the dysregulated inflammasome-based molecular functionome in the malignant transformation of endometriosis-associated ovarian carcinoma. CCC, EAOC, ES, GEO
442  2018 Interleukin-1 receptor-associated kinase 1 correlates with metastasis and invasion in endometrial carcinoma. IRAK1, KEGG
443  2018 Knockdown of CLDN6 inhibits cell proliferation and migration via PI3K/AKT/mTOR signaling pathway in endometrial carcinoma cell line HEC-1-B. CCK-8, Cldn6, PI3K
444  2018 Knockdown of long non-coding HOTAIR enhances the sensitivity to progesterone in endometrial cancer by epigenetic regulation of progesterone receptor isoform B. ChIP, MPA, PRB
445  2018 L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. L1CAM, ProMisE
446  2018 Liposomal Curcumin Targeting Endometrial Cancer Through the NF-kappaB Pathway. LC, Lipo
447  2018 LOC134466 methylation promotes oncogenesis of endometrial carcinoma through LOC134466/hsa-miR-196a-5p/TAC1 axis. lncRNA
448  2018 Long noncoding RNA HOTAIR mediates the estrogen-induced metastasis of endometrial cancer cells via the miR-646/NPM1 axis. HOX, NPM1
449  2018 Markers of the epithelial-mesenchymal transition in cells of endometrial carcinoma. EMT
450  2018 Maximizing Sentinel Lymph Node Detection: Aortic Sentinel Lymph Node Detection in Endometrial Cancer. ICG, SLNs
451  2018 MELF pattern of myometrial invasion and role in possible endometrial cancer diagnostic pathway: A systematic review of the literature. DFS, DSS, MELF
452  2018 MicroRNA 302b-3p/302c-3p/302d-3p inhibits epithelial-mesenchymal transition and promotes apoptosis in human endometrial carcinoma cells. EMT, FITC, PI, qRT-PCR
453  2018 MicroRNA-381 inhibits cell proliferation and invasion in endometrial carcinoma by targeting the IGF-1R. ERK, miRNAs
454  2018 miR-101-3p induces autophagy in endometrial carcinoma cells by targeting EZH2. TEM
455  2018 Nuclear beta-catenin and CDX2 Expression in Ovarian Endometrioid Carcinoma Identify Patients with Favorable Outcome. OCSS
456  2018 Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions. IHC
457  2018 Performance Characteristics of Endometrial Sampling in Diagnosis of Endometrial Carcinoma. AH
458  2018 Pregnancy outcomes of women who received conservative therapy for endometrial carcinoma or atypical endometrial hyperplasia. AH, MPA
459  2018 Preoperative Anemia as a Prognostic Factor in Endometrioid-Type Endometrial Carcinoma. DFS, OS
460  2018 Preoperative tumor size is associated with deep myometrial invasion and lymph node metastases and is a negative prognostic indicator for patients with endometrial carcinoma. AP, AUC, CC, MRI, OS, TV
461  2018 Prognostic Significance of Nodal Location and Ratio in Stage IIIC Endometrial Carcinoma Among a Multi-Institutional Academic Collaboration. CT, DFS, HR, LNs, OS, PC, pLN, RT
462  2018 Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein Deficiency. PD-L1
463  2018 Risk and prognostic factors for endometrial carcinoma after diagnosis of breast or Lynch-associated cancers-A population-based analysis. LS, MMR
464  2018 Serum calcium is a novel parameter to assess metabolic syndrome in endometrial carcinoma. EEC, FPG, HDL, LDL, NEEC, TC, TG
465  2018 Silibinin inhibits endometrial carcinoma via blocking pathways of STAT3 activation and SREBP1-mediated lipid accumulation. ---
466  2018 Studies on selected molecular factors in endometrial cancers. ---
467  2018 The PTENP1 Pseudogene, Unlike the PTEN Gene, Is Methylated in Normal Endometrium, As Well As in Endometrial Hyperplasias and Carcinomas in Middle-Aged and Elderly Females. EH
468  2018 The relationship between lncRNA PCGEM1 and STAT3 during the occurrence and development of endometrial carcinoma. qRT
469  2018 The role of EpCAM in tumor progression and the clinical prognosis of endometrial carcinoma. ---
470  2018 The role of lncRNAs in the development of endometrial carcinoma. lncRNAs
471  2018 The Yokohama system for reporting directly sampled endometrial cytology: The quest to develop a standardized terminology. ---
472  2018 Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma. CC, HGSC, PFS
473  2018 Tumor Heterogeneity in Endometrial Carcinoma: Practical Consequences. ---
474  2018 Type I Versus Type II Endometrial Cancer: Differential Impact of Comorbidity. CCI, OCCI
475  2018 Ultrastaging of Sentinel Lymph Nodes in Endometrial Carcinoma According to Use of 2 Different Methods. IHC, SLN, US
476  2018 Uterine endometrial carcinoma with DNA mismatch repair deficiency: magnetic resonance imaging findings and clinical features. MMR, MRI
477  2018 What Is the Optimal Adjuvant Treatment Sequence for Node-Positive Endometrial Cancer? Results of a National Cancer Database Analysis. CT, HR, OS, RT
478  2018 Zone Formation of Lymphocyte Infiltration at Invasive Front as a Biomarker of Prognosis in Endometrial Carcinomas. LI, OS, PFS
479  2018 [Expression and clinical significance of MIIP and PAK1 in endometrial carcinoma]. AHE, FIGO, MIIP, NE, PAK1
480  2018 [Expression of phosphoglycerate kinase 1 in endometrial carcinoma and its association with patients' outcome]. PGK1
481  2019 Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade). ---
482  2019 The ability of ADC measurements in the assessment of patients with stage I endometrial carcinoma based on three risk categories. ADC, DWI, MRI